Discover and read the best of Twitter Threads about #immunonc
Most recents (1)
Cost-Effectiveness Analysis of Durvalumab Plus Chemotherapy in the First-Line Treatment of Extensive-Stage Small Cell Lung Cancer in: Journal of the National Comprehensive Cancer Network. #lcsm #immunonc jnccn.org/view/journals/…
Durvalumab + chemotherapy resulted in an additional 0.27 LYs and 0.20 QALYs, resulting in an ICER of $464,711.90 per QALY versus the chemotherapy treatment. The cost of durvalumab has the greatest influence on this model. More mature follow-up needed for a more stable model, tho. 
